Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2026 09:00 ET | Source: MannKind

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is...
February 18, 2026 09:00 ET | Source: MannKind

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through...
February 09, 2026 06:05 ET | Source: MannKind

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
January 26, 2026 06:05 ET | Source: MannKind

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin
January 08, 2026 08:05 ET | Source: MannKind

MannKind Provides Business Updates and 2026 Growth Drivers

MannKind Provides Business Updates and 2026 Growth Drivers
December 23, 2025 08:05 ET | Source: MannKind

MannKind Shares FUROSCIX® Business Updates

MANNKIND SHARES FUROSCIX® BUSINESS UPDATES
December 01, 2025 08:05 ET | Source: MannKind

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

MannKind Announces U.S. FDA Accepts for Review its sNDA of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in adults with CHF or CKD
November 11, 2025 16:05 ET | Source: MannKind

MannKind to Present at the Jefferies Global Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss,...
November 10, 2025 08:00 ET | Source: MannKind

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
November 06, 2025 09:00 ET | Source: MannKind

MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes